PharmaTimes: News RSS
GSK, Plasticell sign deal to produce haematopoietic cells
GlaxoSmithKline and Plasticell have signed a collaboration agreement to produce haematopoietic cells from induced pluripotent stem cells (iPSCs).
GP referrals to Weight Watchers cut diabetes risk
More than one third of patients referred by GPs to Weight Watchers in a bid to stave off diabetes saw their blood sugar levels return to normal, a study published in the British Medical Journal has found.
New analysis backs use of Takeda’s Entyvio
Takeda has presented data from a post-hoc analysis showing signs of early symptomatic improvement in patients with ulcerative colitis or Crohn’s disease taking Entyvio.
PRIME status for Ignyta’s entrectinib
European regulators have awarded Ignyta’s cancer drug entrectinib Priority Medicines (PRIME) designation, potentially placing the treatment on a faster path to approval.
‘No-deal’ Brexit could cost NHS £500m a year
A ‘no-deal’ Brexit that ends healthcare arrangements between the UK and the EU could end up costing the NHS as much as £500 million a year, warns a new paper published by the Brexit Healthcare Alliance, on the back of an analysis by the Nuffield Trust.
Pfizer’s lorlatinib impresses in Phase II lung cancer trial
Pfizer has presented Phase II data showing that its next-generation tyrosine kinase inhibitor lorlatinib exhibited “clinically meaningful activity” against lung tumours and brain metastases.
AstraZeneca’s Imfinzi gets speedy US review for lung cancer
US regulators have accepted an application by AstraZeneca and MedImmune to expand the scope of Imfinzi to include patients with a certain form of lung cancer.
Promising data for Sanofi, Regeneron’s dupilumab
Sanofi and Regeneron have unveiled positive results from a mid-stage study exploring the potential of the biologic dupilumab in adults with eosinophilic esophagitis, and also signed a deal with Aimmune Therapeutics to test an experimental peanut allergy therapy.
CHMP backs one generic and six label extensions
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended just one generic medicine for approval at its October meeting.
US expands scope of J&J’s biologic Stelara in psoriasis
US regulators have approved an expansion of Johnson & Johnson’s Stelara to include younger patients with plaque psoriasis.
AI could bring £630bn to UK by 2035
Artificial Intelligence has the potential to add £630 billion to the UK economy by 2035, concludes an independent review commissioned by the government as part of its Industrial Strategy.
Roche links with Warp Drive Bio in antibiotics deal
Roche has entered into a collaboration with Warp Drive Bio aiming to discover and develop multiple classes of antibiotics with novel structures and mechanisms of action.
Renowned journalists Clive Myrie and Babita Sharma team up to present the 2017 Marketer & Communications Team of the Year Awards
Organised by PharmaTimes Media and taking place at the London Marriott Hotel, Grosvenor Square on Thursday 9 November, the PharmaTimes Marketer & Communications Team of the Year Awards will be presented by two of the most recognisable faces in TV current affairs, Clive Myrie and Babita Sharma.
New deal secures Opdivo an NHS spot for head and neck cancer
Bristol-Myers Squibb’s Opdivo will be available on the NHS for squamous cell carcinoma of the head and neck after all, following a u-turn by the National Institute for Health and Care Excellence.
Roche’s skin cancer drug Erivedge pulled from CDF
Roche’s Erivedge could be removed from the Cancer Drugs Fund within months after the National Institute for Health and Care Excellence ruled that the drug was not a cost-effective treatment for skin cancer.
Feed Fetched by RSS Dog.